Wainberg Mark A
McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
AIDS. 2004 Jun;18 Suppl 3:S63-8. doi: 10.1097/00002030-200406003-00012.
Genetic diversity is a hallmark of HIV-1 infection with regard to the expansion of distinct viral subtypes (clades A, B, C, D, E, F, G, K, and O) in different geographical regions. Here, we discuss the issues of HIV-1 sensitivity to antiretroviral drugs and drug resistance in the context of HIV-1 subtype diversity. Virtually all available evidence suggests that all subtypes of HIV display similar sensitivity to antiviral drugs, but viruses from some subtypes or geographical regions may occasionally have a greater propensity to develop resistance against certain drugs than other viral variants. In some situations, the types of mutations associated with resistance may vary, as a result of subtle differences among subtypes with regard to the genetic code. This consideration notwithstanding, drug resistance is unlikely to become a more serious issue in developing than developed countries, and there is an urgency to make anti-HIV drugs available to all who are in need.
就不同地理区域中不同病毒亚型(A、B、C、D、E、F、G、K和O组)的扩张而言,基因多样性是HIV-1感染的一个标志。在此,我们在HIV-1亚型多样性的背景下讨论HIV-1对抗逆转录病毒药物的敏感性和耐药性问题。几乎所有现有证据表明,HIV的所有亚型对抗病毒药物都表现出相似的敏感性,但某些亚型或地理区域的病毒偶尔可能比其他病毒变体更易对某些药物产生耐药性。在某些情况下,由于亚型之间在遗传密码方面的细微差异,与耐药性相关的突变类型可能会有所不同。尽管有这一考虑因素,但耐药性在发展中国家不太可能比发达国家成为更严重的问题,而且迫切需要向所有有需要的人提供抗HIV药物。